Tabucym 30 mg. 60 mg Capsules
PDF Leaflet Revision Date: 13 April 2021
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of depression and diabetic peripheral neuropathic pain.
Dosage (summary)
60 mg once daily for adults; 30 mg for mild to moderate renal impairment.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; potential risks include neonatal withdrawal symptoms.
Key Drug Interactions
- MAOIs
- CYP1A2 inhibitors
- CYP2D6 inhibitors
- Serotonergic agents
Contraindications
- Hypersensitivity to duloxetine
- Severe hepatic impairment
- Advanced renal impairment
- Concomitant MAOIs
- Children under 18
Common side effects
- Nausea
- Headache
- Dry mouth
- Somnolence
- Dizziness
Counselling Points
- Avoid abrupt discontinuation
- Monitor for suicidal thoughts
- Caution with alcohol and CNS depressants
Serious warnings
- Increased risk of suicidal thoughts
- Serotonin syndrome
- Hypertension
- Withdrawal symptoms
Important Disclaimer
The Tabucym 30 mg. 60 mg Capsules professional information leaflet below is the property of Aurogen Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
